IN · State regulatory reference

Indiana.

Active change

Indiana's distinctive signal is fresh, peptide-relevant legislation. Senate Bill 282, signed by the Governor on March 5, 2026 as Public Law 136 (2026), sets drug-compounding requirements and — beginning January 1, 2027 — requires med spas to register with the Medical Licensing Board of Indiana, designate a responsible practitioner, report serious adverse events, and submit to board investigation. Telehealth practice runs under IC 25-1-9.5, which holds telehealth to the in-person standard of care and lets a prescriber issue a prescription without a prior in-person exam if that standard is met. Compounding otherwise tracks the baseline USP framework under 856 IAC (the Board's interim rule to adopt updated USP chapters was postponed, not tightened).

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Indiana Medical Board

https://www.in.gov/pla/professions/medical-licensing-board-home/ ↗

Pharmacy board

Indiana Board of Pharmacy

https://www.in.gov/pla/professions/indiana-board-of-pharmacy-home/ ↗

TPC notes

Telehealth

Under IC 25-1-9.5, an initial visit and prescribing may be established via synchronous telehealth without a prior in-person exam if the standard of care is met; asynchronous-only tools do not qualify absent an established relationship, and controlled substances require real-time audio-video plus INSPECT (PDMP) compliance.

Compounding

The Board of Pharmacy regulates 503A compounding under 856 IAC on the baseline USP framework; SB 282 / Public Law 136 (2026) layers on GLP-1-era oversight, empowering the board on compounding and requiring med-spa registration and a responsible practitioner from January 1, 2027.

Sources